Wednesday, May 22 2013 5:16 AM EDT2013-05-22 09:16:17 GMT
Nearly 60-thousand "Lea" panel, loft and bunk beds in various sizes are being recalled. It turns out the side mattress support rails can break, posing a fall hazard. The rails are on 34 different LeaMore >>
Nearly 60-thousand "Lea" panel, loft and bunk beds in various sizes are being recalled.More >>
Wednesday, May 22 2013 11:48 PM EDT2013-05-23 03:48:10 GMT
Combat is something few Korean War Veterans want to remember. They suppress the memories. Army Veteran Bobby Todd served in the Korean War. He says he never talked about his experiences in the war untilMore >>
The fighting may be over, but the memories remain. Local Korean War veterans share their memories of fighting in the Korean War for a documentary. More >>
Wednesday, May 22 2013 11:45 PM EDT2013-05-23 03:45:43 GMT
Law enforcement from Indiana and Kentucky were in the 14 News Interactive Center answering your calls and taking any tips to help catch those most wanted. Some of the cases we've featured have ended withMore >>
law enforcement from Indiana and Kentucky were in the 14 News Interactive Center Tuesday night answering your calls and taking any tips to help catch those most wanted. Some of the cases we've featured have ended with suspects in custody.More >>
Wednesday, May 22 2013 10:54 PM EDT2013-05-23 02:54:14 GMT
Those who knew the victim of a deadly shooting in Princeton speak out to 14 News about the struggles they say she had with the suspect. Authorities tells 14 News the suspect, Jason Perry is in the GibsonMore >>
Those who knew the victim of a deadly shooting in Princeton speak out to 14 News about the struggles they say she had with the suspect.More >>
Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.
SOURCE Venaxis, Inc.
Market Development Efforts to be Initiated in Italy and Turkey
CASTLE ROCK, Colo., March 18, 2013 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE-Marked blood-based appendicitis test, APPY1, today announced it has executed two additional commercial development agreements as part of the initial phase of the European launch. MOSS S.p.A. of Italy and SAVAS Medikal Inc. of Turkey have committed to market development activities within their respective territories and each have submitted initial stocking purchase orders for the APPY1 test/system. Venaxis announced a similar agreement with EMELCA Bioscience earlier this year that covers Belgium, Luxembourg, and the Netherlands.
Don Hurd, Senior Vice President and Chief Commercial Officer of Venaxis, stated, "We are pleased to continue gaining traction in Europe as we roll out our market development program for APPY1. The positive feedback we're receiving from physicians, surgeons, and laboratory personnel at key hospitals in our target regions continues to be encouraging and we look forward to advancing these efforts to maximize the European commercial opportunity for APPY1. We have begun working with both companies to identify top hospital accounts in Italy and Turkey that are best suited to support our market development plan."
MOSS S.p.A., based near Milan, covers all hospitals across Italy, which collectively record approximately 24 million emergency department visits per year. SAVAS Medikal Inc., based in Istanbul, covers all hospitals across Turkey and these hospitals estimate a total of 35 million emergency visits per year.
Franco Papa, President and CEO of MOSS S.p.A., stated, "We specialize in identifying high-tech, innovative medical solutions designed to provide answers to our end users' most specific diagnostic demands. We are pleased to advance with Venaxis because we believe APPY1 fits well within that core philosophy and our focus and experience in diagnostics. We are very encouraged by APPY1's product profile and we look forward to developing the Italian market through this strategic collaboration."
Savas Sakar, CEO and President of SAVAS Medikal Inc., stated, "We are excited to collaborate with Venaxis for APPY1 and look forward to building a mutually successful business relationship. Based upon our significant market experience we believe we can, in conjunction with Venaxis, execute an efficient and fruitful market development program in Turkish hospitals."
About Venaxis, Inc. Venaxis, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its CE-Marked blood-based appendicitis test, APPY1. This unique appendicitis test has projected high sensitivity and negative predictive value and is being developed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management. APPY1 is being developed initially for pediatric, adolescent and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging. While FDA clearance is being sought, an initial launch for APPY1 is ongoing in select European territories. For more information, visit www.venaxis.com.
Forward-Looking Statements This press release includes "forward-looking statements" of Venaxis, Inc. ("Venaxis") (formerly AspenBio Pharma, Inc.) as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that Venaxis believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors Venaxis believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Venaxis. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial activities for APPY1 required for FDA submission, obtain FDA clearance or approval, maintain CE Marking, cost effectively manufacture and generate revenues from APPY1 at a profitable price point, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, Venaxis does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in Venaxis' recent filings with the SEC, including its Form 10-Q for the period ended September 30, 2012, filed on November 7, 2012.
Wednesday, May 22 2013 6:00 PM EDT2013-05-22 22:00:02 GMT
An Evansville Police Officer was injured while trying to arrest a fleeing drug dealer on Tuesday afternoon. Police stopped an SUV after the driver committed several traffic violations. Officers pulledMore >>
Police stop an SUV on the north side of Bayard Park. The result: an officer injured, a chase with a suspect, and three men arrested on a variety of charges.More >>
Tuesday, May 21 2013 3:29 PM EDT2013-05-21 19:29:04 GMT
For months, concerns had been raised about the welfare of Lucas Webb. Born Jan. 3, 2008, Lucas knew much pain and suffering in his four short years. More >>
State records released Monday show how Missouri social workers failed to adequately pursue allegations of abuse involving a preschooler. Lucas Webb, 4, would die five days after the state closed the abuse investigation.More >>
Wednesday, May 22 2013 6:21 PM EDT2013-05-22 22:21:12 GMT
(RNN) - British officials are saying one man is dead and two others were injured in a possible terrorist attack in London on Wednesday.According to BBC News, eyewitnesses said man was attacked in a streetMore >>
One man is dead after two men attacked him in broad daylight with knives and meat cleavers. More >>
Wednesday, May 22 2013 9:06 PM EDT2013-05-23 01:06:34 GMT
Gibson Co. dispatch confirms a report of shots fired in the area of Los Aztecas on W. Broadway in Princeton. According to our media partner, the Princeton Daily Clarion, shooting suspect fled the sceneMore >>
Princeton Police Chief W.W. George tells 14 News the suspect, believed to be her boyfriend, shot the woman as she and her 13-year-old son were walking in the Los Aztecas parking lotMore >>
Tuesday, May 21 2013 2:46 PM EDT2013-05-21 18:46:43 GMT
We are excited to announce you'll now be able to watch all of our newscasts, and severe and breaking news on your iPhone or iPad (It may work on some Android phones, too, but you may need to wait for anMore >>
We should be on the air (minus commercials) from 4:30-7:00 AM; from 11:00-12:00 AM; from 4-5:30 PM; from 6:00-6:30 PM; and from 10:00-10:30 PM. Plus anytime we are on the air for breaking news or weather, we'll be broadcasting live on your phoneMore >>